A radical role for p38 MAPK in tumor initiation.

abstract：:Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma. Allosteric mTOR inhibitors, such as rapamycin, incompletely block mT...

journal_title：Cancer cell

authors： Fan Q,Aksoy O,Wong RA,Ilkhanizadeh S,Novotny CJ,Gustafson WC,Truong AY,Cayanan G,Simonds EF,Haas-Kogan D,Phillips JJ,Nicolaides T,Okaniwa M,Shokat KM,Weiss WA

更新日期：2017-03-13 00:00:00

abstract：:8p11 myeloproliferative syndrome (EMS) is a hematopoietic stem cell disorder characterized by myeloid hyperplasia and non-Hodgkin's lymphoma with chromosomal translocations fusing several genes, most commonly ZNF198, to fibroblast growth factor receptor-1 (FGFR1). However, patients with BCR-FGFR1 fusion present with t...

journal_title：Cancer cell

authors： Roumiantsev S,Krause DS,Neumann CA,Dimitri CA,Asiedu F,Cross NC,Van Etten RA

更新日期：2004-03-01 00:00:00

abstract：:A definitive knockout reported in this issue of Cancer Cell by Sicinska et al. reveals an unsuspected role for cyclin D3 in normal T cell development and suggests new therapeutic possibilities in precursor T cell leukemia. ...

journal_title：Cancer cell

authors： Weng AP,Aster JC

更新日期：2003-12-01 00:00:00

abstract：:Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade is mediated ...

journal_title：Cancer cell

authors： Ngiow SF,McArthur GA,Smyth MJ

更新日期：2015-04-13 00:00:00

abstract：:ErbB2, a metastasis-promoting oncoprotein, is overexpressed in approximately 25% of invasive/metastatic breast cancers, but in 50%-60% of noninvasive ductal carcinomas in situ (DCIS). It has been puzzling how a subset of ErbB2-overexpressing DCIS develops into invasive breast cancer (IBC). We found that co-overexpress...

journal_title：Cancer cell

authors： Lu J,Guo H,Treekitkarnmongkol W,Li P,Zhang J,Shi B,Ling C,Zhou X,Chen T,Chiao PJ,Feng X,Seewaldt VL,Muller WJ,Sahin A,Hung MC,Yu D

更新日期：2009-09-08 00:00:00

abstract：:STAT3 plays many roles in tumorigenesis. In this issue of Cancer Cell, Kortylewski et al. show that in the tumor microenvironment, STAT3 enhances the expression of the protumor cytokine IL-23 in macrophages but inhibits the antitumor cytokine IL-12 in dendritic cells. STAT3 also mediates IL-23's effect of activating t...

journal_title：Cancer cell

authors： Stewart CA,Trinchieri G

更新日期：2009-02-03 00:00:00

abstract：:Activating mutations in GNAQ/GNA11, encoding Gαq G proteins, are initiating oncogenic events in uveal melanoma (UM). However, there are no effective therapies for UM. Using an integrated bioinformatics pipeline, we found that PTK2, encoding focal adhesion kinase (FAK), represents a candidate synthetic lethal gene with...

journal_title：Cancer cell

authors： Feng X,Arang N,Rigiracciolo DC,Lee JS,Yeerna H,Wang Z,Lubrano S,Kishore A,Pachter JA,König GM,Maggiolini M,Kostenis E,Schlaepfer DD,Tamayo P,Chen Q,Ruppin E,Gutkind JS

更新日期：2019-03-18 00:00:00

abstract：:ARID1A encodes an SWI/SNF chromatin-remodeling factor and is frequently mutated in various cancers. This study demonstrates that ARID1A-deficient cancer cells are specifically vulnerable to inhibition of the antioxidant glutathione (GSH) and the glutamate-cysteine ligase synthetase catalytic subunit (GCLC), a rate-lim...

journal_title：Cancer cell

authors： Ogiwara H,Takahashi K,Sasaki M,Kuroda T,Yoshida H,Watanabe R,Maruyama A,Makinoshima H,Chiwaki F,Sasaki H,Kato T,Okamoto A,Kohno T

更新日期：2019-02-11 00:00:00

abstract：:Targeting chromatin regulators for the treatment of malignancies has shown great promise, but also revealed significant challenges. By employing an elegant shRNA screen and a selective pharmacological inhibitor, a recent study published in Nature establishes the bromodomain protein Brd4 as novel target in acute myeloi...

journal_title：Cancer cell

authors： Blobel GA,Kalota A,Sanchez PV,Carroll M

更新日期：2011-09-13 00:00:00

abstract：:Specific phosphoinositide lipids promote cell growth and cancer. In this issue of Cancer Cell, Fayngerts and colleagues demonstrate that the TIPE3 protein enhances PtdIns(4,5)P2 and PtdIns(3,4,5)P3, is overexpressed in certain cancers, and promotes tumorigenesis. TIPE3 can act as a lipid transfer protein and may const...

journal_title：Cancer cell

authors： Moniz LS,Vanhaesebroeck B

更新日期：2014-10-13 00:00:00

abstract：:Angiogenesis is a hallmark of solid tumors, and disruption of tumor vasculature is an active anticancer therapy in some cases. Several proteins expressed on the surface of tumor endothelium have been identified during the last decade. However, due to the expression in both physiological and tumor angiogenesis, only a ...

journal_title：Cancer cell

authors： Li JL,Harris AL

更新日期：2007-06-01 00:00:00

abstract：:Perturbation biology is a powerful approach to modeling quantitative cellular behaviors and understanding detailed disease mechanisms. However, large-scale protein response resources of cancer cell lines to perturbations are not available, resulting in a critical knowledge gap. Here we generated and compiled perturbed...

journal_title：Cancer cell

authors： Zhao W,Li J,Chen MM,Luo Y,Ju Z,Nesser NK,Johnson-Camacho K,Boniface CT,Lawrence Y,Pande NT,Davies MA,Herlyn M,Muranen T,Zervantonakis IK,von Euw E,Schultz A,Kumar SV,Korkut A,Spellman PT,Akbani R,Slamon DJ,Gray

更新日期：2020-12-14 00:00:00

abstract：:PPARgamma is a member of the nuclear receptor family for which agonist ligands have antigrowth effects. However, clinical studies using PPARgamma ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARgamma activation with chemotherapeutic agents in current use for specifi...

journal_title：Cancer cell

authors： Girnun GD,Naseri E,Vafai SB,Qu L,Szwaya JD,Bronson R,Alberta JA,Spiegelman BM

更新日期：2007-05-01 00:00:00

abstract：:Malignant melanoma is characterized by frequent metastasis, however, specific changes that regulate this process have not been clearly delineated. Although it is well known that Wnt signaling is frequently dysregulated in melanoma, the functional implications of this observation are unclear. By modulating β-catenin le...

journal_title：Cancer cell

authors： Damsky WE,Curley DP,Santhanakrishnan M,Rosenbaum LE,Platt JT,Gould Rothberg BE,Taketo MM,Dankort D,Rimm DL,McMahon M,Bosenberg M

更新日期：2011-12-13 00:00:00

abstract：:Therapeutic resistance is a major challenge in cancer treatment. In this issue of Cancer Cell, Kurppa et al. demonstrated that a senescence-like state enables lung cancer cells to survive dual inhibition of EGFR and MEK. This was mediated by the YAP/TEAD pathway, which drives epigenomic reprogramming and EMT to counte...

journal_title：Cancer cell

authors： Bado I,Zhang XH

更新日期：2020-01-13 00:00:00

abstract：:Transcription factor NF-kappaB has been implicated in cancer development due to its ability to upregulate expression of genes with potentially prooncogenic functions, such as cell cycle regulators and antiapoptotic proteins (Karin et al., 2002). A recent report by suggests that a structural motif, a death domain (DD),...

journal_title：Cancer cell

authors： Häcker H,Karin M

更新日期：2002-12-01 00:00:00

abstract：:Therapies that target estrogen signaling have transformed the treatment of breast cancer. However, the effectiveness of these agents is limited by the development of resistance. Here, an RNAi screen was used to identify modifiers of tamoxifen sensitivity. We demonstrate that CDK10 is an important determinant of resist...

journal_title：Cancer cell

authors： Iorns E,Turner NC,Elliott R,Syed N,Garrone O,Gasco M,Tutt AN,Crook T,Lord CJ,Ashworth A

更新日期：2008-02-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL) is caused by chromosomal translocations that involve the retinoic acid receptor alpha (RAR) and several other genes to yield X-RAR fusion proteins. Unlike wild-type RARs, which require heterodimerization with the retinoid X receptor (RXR) for their function as DNA-binding transcripti...

journal_title：Cancer cell

authors： Minucci S,Pelicci PG

更新日期：2007-07-01 00:00:00

abstract：:HIF-2alpha promotes von Hippel-Lindau (VHL)-deficient renal clear cell carcinoma (RCC) tumorigenesis, while HIF-1alpha inhibits RCC growth. As HIF-1alpha antagonizes c-Myc function, we hypothesized that HIF-2alpha might enhance c-Myc activity. We demonstrate here that HIF-2alpha promotes cell-cycle progression in hypo...

journal_title：Cancer cell

authors： Gordan JD,Bertout JA,Hu CJ,Diehl JA,Simon MC

更新日期：2007-04-01 00:00:00

abstract：:In this issue of Cancer Cell, Kudo et al. identify a novel tumor suppressor role for PKCλ/ι in hepatocellular carcinoma. Loss of PKCλ/ι in obesity-driven liver cancer results in cellular metabolic reprogramming that induces two reciprocally sustainable processes, oxidative phosphorylation and autophagy, which promote ...

journal_title：Cancer cell

authors： Ramadori P,Li X,Heikenwalder M

更新日期：2020-08-10 00:00:00

abstract：:Pro-inflammatory cytokines produced in the tumor microenvironment lead to eradication of anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified tumor necrosis factor alpha (TNF-α) as a major factor triggering cancer cell immunosuppression against T cell surveillance via stabilization...

journal_title：Cancer cell

authors： Lim SO,Li CW,Xia W,Cha JH,Chan LC,Wu Y,Chang SS,Lin WC,Hsu JM,Hsu YH,Kim T,Chang WC,Hsu JL,Yamaguchi H,Ding Q,Wang Y,Yang Y,Chen CH,Sahin AA,Yu D,Hortobagyi GN,Hung MC

更新日期：2016-12-12 00:00:00

abstract：:Glioma-initiating cells (GICs) are responsible for the initiation and recurrence of gliomas. Here, we identify a molecular mechanism that regulates the self-renewal capacity of patient-derived GICs. We show that TGF-beta and LIF induce the self-renewal capacity and prevent the differentiation of GICs. TGF-beta induces...

journal_title：Cancer cell

authors： Peñuelas S,Anido J,Prieto-Sánchez RM,Folch G,Barba I,Cuartas I,García-Dorado D,Poca MA,Sahuquillo J,Baselga J,Seoane J

更新日期：2009-04-07 00:00:00

abstract：:Therapeutic resistance in melanoma and other cancers arises via irreversible genetic, and dynamic phenotypic, heterogeneity. Here, we use directed phenotype switching in melanoma to sensitize melanoma cells to lineage-specific therapy. We show that methotrexate (MTX) induces microphthalmia-associated transcription fac...

journal_title：Cancer cell

authors： Sáez-Ayala M,Montenegro MF,Sánchez-Del-Campo L,Fernández-Pérez MP,Chazarra S,Freter R,Middleton M,Piñero-Madrona A,Cabezas-Herrera J,Goding CR,Rodríguez-López JN

更新日期：2013-07-08 00:00:00

abstract：:The link between GBM molecular subtype and response to treatment remains undefined. In this issue of Cancer Cell, Cosset and colleagues define a subpopulation of patients within the proneural/classical subtype sensitive to integrin blockade because of a Glut3 addiction. These findings reveal context-dependent druggabl...

journal_title：Cancer cell

authors： Bunda S,Zadeh G,Aldape KD

更新日期：2017-12-11 00:00:00

abstract：:In this issue of Cancer Cell, Fedoriw and colleagues characterize a potent reversible inhibitor of type I PRMTs, GSK3368715, with anti-proliferative effects on numerous cancer types. Using a combination of GSK3368715 with PRMT5 inhibitors, the authors show that a threshold of overall arginine methylation reduction nee...

journal_title：Cancer cell

authors： Srour N,Mersaoui SY,Richard S

更新日期：2019-07-08 00:00:00

abstract：:Gankyrin is an ankyrin repeat oncoprotein commonly overexpressed in hepatocellular carcinomas. Gankyrin interacts with the S6 proteasomal ATPase and accelerates the degradation of the tumor suppressor Rb. We show here that gankyrin has an antiapoptotic activity in cells exposed to DNA damaging agents. Downregulation o...

journal_title：Cancer cell

authors： Higashitsuji H,Higashitsuji H,Itoh K,Sakurai T,Nagao T,Sumitomo Y,Masuda T,Dawson S,Shimada Y,Mayer RJ,Fujita J

更新日期：2005-07-01 00:00:00

abstract：:Targeted protein degradation is an emerging technology for drug development. An article published in Nature reported a novel mechanism of targeted protein degradation triggered by small-molecule-induced polymerization of the oncogenic transcription factor BCL6. ...

journal_title：Cancer cell

authors： Naito M,Murata S

更新日期：2021-01-11 00:00:00

abstract：:The Twist1 transcription factor is known to promote tumor metastasis and induce Epithelial-Mesenchymal Transition (EMT). Here, we report that Twist1 is capable of promoting the formation of invadopodia, specialized membrane protrusions for extracellular matrix degradation. Twist1 induces PDGFRα expression, which in tu...

journal_title：Cancer cell

authors： Eckert MA,Lwin TM,Chang AT,Kim J,Danis E,Ohno-Machado L,Yang J

更新日期：2011-03-08 00:00:00

abstract：:The tumor suppressor cylindromatosis (CYLD) inhibits the NFκB and mitogen-activated protein kinase (MAPK) activation pathways by deubiquitinating upstream regulatory factors. Here we show that liver-specific disruption of CYLD triggers hepatocyte cell death in the periportal area via spontaneous and chronic activation...

journal_title：Cancer cell

authors： Nikolaou K,Tsagaratou A,Eftychi C,Kollias G,Mosialos G,Talianidis I

更新日期：2012-06-12 00:00:00

abstract：:The proapoptotic death receptor DR5 has been studied extensively in cancer cells, but its action in the tumor microenvironment is not well defined. Here, we uncover a role for DR5 signaling in tumor endothelial cells (ECs). We detected DR5 expression in ECs within tumors but not normal tissues. Treatment of tumor-bear...

journal_title：Cancer cell

authors： Wilson NS,Yang A,Yang B,Couto S,Stern H,Gogineni A,Pitti R,Marsters S,Weimer RM,Singh M,Ashkenazi A

更新日期：2012-07-10 00:00:00